H.C. Wainwright raised the firm’s price target on Regenxbio to $39 from $38 and keeps a Buy rating on the shares post the Q2 report. The firm says new Duchenne muscular dystrophy data support plans for accelerated approval of RGX-202.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Regenxbio reports Q2 EPS ($1.05), consensus ($1.29)
- REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
- Biotech Alert: Searches spiking for these stocks today
- Regenxbio’s RGX-202 shows positive Phase 1/2 results in Duchenne
- RegenXBio Inc. (RGNX) Q2 Earnings Cheat Sheet